Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Anna-CPRC-TBD | Other Identifier | UMN Clinical Protocol Review Committee |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects..
This is a pilot trial to evaluate the feasibility of conducting a large randomized trial and estimate the effects of ginger extract on the gut microbiome. The pilot study will recruit from multiple sites 95-100 subjects aged 50-75 years old who were diagnosed with colorectal adenoma within the last five years. There will be 47-50 subjects in the treatment group and 47-50 in the placebo group. The subjects will be randomized to receive either 2000 mg of ginger extract per day (1000 mg twice a day) or matching placebo.
Subjects will provide three stool specimens for analysis of the intestinal microbiome over a 12-week period at the following intervals: Week 0 (Day 1), Week 6, and Week 12. Although the gut microbiome is stable within a period of 1-2 months, a control arm will be included to account for potential dietary and other changes that may affect the gut microbiome. Gut microbiome composition - the presence, abundance, and diversity of bacterial taxa - will be derived by sequencing microbial 16S ribosomal RNA genes.
Primary Aims:
Aim 1 is to estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects.
Aim 2 will examine the correlation between the ginger-related changes in microbiome profile with the levels of circulating biomarkers: urinary Prostaglandin E (PGE) metabolites.
Hypothesis: In the ginger versus placebo arm, gut microbiome will shift towards a lower proportion of pro-inflammatory, bacteria associated with colorectal cancer (CRC) and higher proportion of anti-inflammatory, CRC-protective bacteria.
Secondary Aim:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ginger extract | Experimental | Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout. |
|
| Placebo | Experimental | Placebo, daily for 6 weeks, followed by 6 week washout. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ginger extract | Dietary Supplement | 2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout |
|
| Measure | Description | Time Frame |
|---|---|---|
| Composition of the gut microbiome | Fecal microbial diversity and the prevalence of specific taxa associated with colorectal cancer (e.g. Fusobacteria, butyrate producing bacteria) will be estimated at 6 weeks. The ginger-related changes in the prevalence of each taxon will be assessed individually and also combined into a microbiome index (the abundance of protective taxa will be included as a negative value). | Baseline to 6 Weeks |
| Urine inflammatory biomarker | Urinary metabolite of Prostaglandin E2 (ng/mg of creatinine) will be measured before and after treatment with ginger. Changes in inflammatory markers will be correlated to changes in the microbial diversity and the microbiome composition | Baseline to 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in gut microbiome composition | Beta-diversity will be compared between three time points: baseline, 6 Weeks and 12 Weeks. | Baseline to 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anna Prizment, PhD, MPH | University of Minnesota, Epidemiology and Community Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Cancer Center | Albert Lea | Minnesota | 56007 | United States | ||
| Mayo Clinic Cancer Center |
The results of the study will be disseminated to various stakeholders through the publication of a manuscript in a peer-reviewed journal and through presentation at scientific meetings.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000713927 | ginger extract |
Not provided
Not provided
Not provided
Pilot. Double-blind placebo-controlled randomized trial
Not provided
Not provided
Double blind
| Placebo | Other | 2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout |
|
| Austin |
| Minnesota |
| 55912 |
| United States |
| Essentia Health - Deer River | Deer River | Minnesota | 56636 | United States |
| Essentia Health St Mary's - Detroit Lakes | Detroit Lakes | Minnesota | 56501 | United States |
| Essentia Health - Fosston Clinic | Fosston | Minnesota | 56542 | United States |
| Fairview Grand Itasca Clinic & Hospital | Grand Rapids | Minnesota | 55744 | United States |
| Fairview Range Medical Center | Hibbing | Minnesota | 55746 | United States |
| Mayo Clinic Cancer System | Mankato | Minnesota | 56001 | United States |
| Epidemiology Clinical Research Center | Minneapolis | Minnesota | 55415 | United States |
| Monticello Cancer Center | Monticello | Minnesota | 55362 | United States |
| Essentia Health - Park Rapids Clinic | Park Rapids | Minnesota | 56470 | United States |
| Fairview Northland Medical Center | Princeton | Minnesota | 55371 | United States |
| Essentia Health -Virgina Clinic | Virginia | Minnesota | 55792 | United States |